Factors affecting topotecan sensitivity in human leukemia samples.
Kaufmann
S H
SH
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. Kaufmann.Scott@Mayo.edu
Gore
S D
SD
Letendre
L
L
Svingen
P A
PA
Kottke
T
T
Buckwalter
C A
CA
Jones
R J
RJ
Grochow
L B
LB
Burke
P J
PJ
Donehower
R C
RC
Rowinsky
E K
EK
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002454:Cell Differentiation; D017321:Clinical Trials, Phase I as Topic; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors; D019772:Topotecan; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D019772:Topotecan; D002166:Camptothecin